Association Between plasma Angiotensinogen level and response to valsartan among sample of hypertensive Iraqi patients
1
Department of Pharmacology and Therapeutics, College of Medicine, University of Al-Qadisiyah, Iraq, Iraq
2
Department of Pharmacology and Therapeutics, College of pharmacy, University of Al-Qadisiyah, Iraq, Iraq
Submission date: 2023-08-07
Final revision date: 2024-04-19
Acceptance date: 2024-07-17
Publication date: 2024-11-03
Corresponding author
Haneen Sajid Mahmoud
Department of Pharmacology and Therapeutics, College of Medicine, University of Al-Qadisiyah, Iraq, Iraq
Department of Pharmacology and Therapeutics, College of Medicine, University of Al-Qadisiyah, Iraq, Iraq
Wiadomości Lekarskie 2024;77(9):1662-1671
KEYWORDS
TOPICS
ABSTRACT
Aim:
Aims: to ascertain if AGT polymorphism [rs699 (T235M), rs5051 (A-6G)] affects the success of valsartan treatment for essential hypertension in Iraqi patients, here, we demonstrate that two of these variations contribute nothing to the clinical response to valsartan.
Material and methods:
Data obtained at the Al-Diwaniyah teaching hospital in Iraq by researchers from the Department of Pharmacology and Therapeutics in the College of Medicine at University of Al-Qadisiyah from July 2022 to July 2023. All participants (aged 20 to 70) had been taking valsartan 160 mg once day for essential hypertension for at least two weeks before to the study. There were a total of 90 participants, 37 males and 53 women. Initial investigations of hypertension have indicated that the angiotensinogen gene has a substantial impact in susceptibility to essential hypertension through observational cross sectional descriptive single center study.
Results:
Indicate, in patients with essential hypertension, that the "AGT gene A>G (rs699) and C>T(rs5051)" have high angiotensinogen level, and there is no significant association between these two (rs699, rs5051) and responsiveness to valsartan (P >0.05).
Conclusions:
There is no significant association between these two (rs699, rs5051) and responsiveness to valsartan (P >0.05).
Aims: to ascertain if AGT polymorphism [rs699 (T235M), rs5051 (A-6G)] affects the success of valsartan treatment for essential hypertension in Iraqi patients, here, we demonstrate that two of these variations contribute nothing to the clinical response to valsartan.
Material and methods:
Data obtained at the Al-Diwaniyah teaching hospital in Iraq by researchers from the Department of Pharmacology and Therapeutics in the College of Medicine at University of Al-Qadisiyah from July 2022 to July 2023. All participants (aged 20 to 70) had been taking valsartan 160 mg once day for essential hypertension for at least two weeks before to the study. There were a total of 90 participants, 37 males and 53 women. Initial investigations of hypertension have indicated that the angiotensinogen gene has a substantial impact in susceptibility to essential hypertension through observational cross sectional descriptive single center study.
Results:
Indicate, in patients with essential hypertension, that the "AGT gene A>G (rs699) and C>T(rs5051)" have high angiotensinogen level, and there is no significant association between these two (rs699, rs5051) and responsiveness to valsartan (P >0.05).
Conclusions:
There is no significant association between these two (rs699, rs5051) and responsiveness to valsartan (P >0.05).
Share
RELATED ARTICLE
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
